Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 734-738

  Boschman, Cynthia R ^a   Bodnar, Ulana R ^a   Tornatore, Michelle A ^a   Obias, Arlene A ^a   Noskin, Gary A ^a   Englund, Kristin ^a   Postelnick, Michael A ^a   Suriano, Terra ^a   Peterson, Lance R ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GENTAMICIN; KETOCONAZOLE; MICONAZOLE; PYRROLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANCER PATIENT; CANDIDA ALBICANS; DECISION MAKING; DRUG RESISTANCE; EVOLUTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; YEAST;

EID: 0031956594     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.734     Document Type: Article

References (39)

1. Anaissie, E. J., R. O. Darouiche, D. Abi-Said, O. Uzun, J. Mera, L. O. Gentry, T. Williams, D. P. Kontoyiannis, C. L. Karl, and G. P. Body. 1996. Management of invasive candidal infections: results of a prospective, randomized multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. 23:964-972.
2. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Toison, T. Henderson, and W. J. Martone. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am. J. Med. 91(Suppl. 3B):86S-89S.
3. Beck-Sague, C. M., W. R. Jarvis, and the National Nosocomial Infections Surveillance System. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis. 167:1247-1251.
4. Brammer, K. W., P. R. Farrow, and J. K. Faulkner. 1990. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12(Suppl. 3):S318-S326.
5. Goa, K. L., and L. B. Barradell. 1995. Fluconazole and update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50:658-690.
6. Goff, D. A., S. L. Koletar, W. J. Buesching, J. Barnishan, and R. J. Fass. 1995. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin. Infect. Dis. 20:77-83.
7. Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stiff, D. J. Friedman, et al. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-851.
8. Hacek, D. M., G. A. Noskin, K. Trakas, and L. R. Peterson. 1995. Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory. J. Clin. Microbiol. 33:1884-1889
9. Iwen, P. C., D. M. Kelly, E. C. Reed, and S. H. Hinrichs. 1995. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis. 20:342-347.
10. Jarvis, W. 1995. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis. 20:1526-1530.
11. Karyotakis, N. C., E. J. Anaissie, R. Hachem, M. C. Dignani, and G. Samonis. 1993. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J. Infect. Dis. 168:1311-1313.
12. Klastersky, J. 1995. Prevention and therapy of fungal infections in cancer patients. A review of recently published information. Support. Care Cancer 3:393-401.
13. Maenza, J. R., J. C. Keruly, R. D. Moore, R. E. Chaisson, W. G. Merz, and J. E. Gallant. 1996. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 173:219-225.
14. Maenza, J. R., W. G. Merz, M. J. Romagnoli, J. C. Keruly, R. D. Moore, and J. E. Gallant. 1997. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin. Infect. Dis. 24:28-34.
15. Meunier, F., and B. Wong. 1993. Overview of management of fungal infections: part 1. Clin. Infect. Dis. 17(Suppl. 2):S492-S493.
16. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
17. National Nosocomial Infections Surveillance System. 1996. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. Am. J. Infect. Control 24:380-388.
18. Newman, S. L., T. P. Flanigan, A. Fisher, M. G. Rinaldi, M. Stein, and K. Vigilante. 1994. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin. Infect. Dis. 19:684-686
19. Nguyen, M. H., J. E. Peacock, A. J. Morris, D. C. Tanner, M. L. Nguyen D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
20. Noskin, G. A., J. Lee, D. M. Hacek, M. Postelnick, B. E. Reisberg, V. Stosor, S. A. Weitzman, and L. R. Peterson. 1996. Molecular typing for investigating an outbreak of Candida krusei. Diagn. Microbiol. Infect. Dis. 26:117-123.
21. Paya, C. V. 1993. Fungal infections in solid-organ transplantation. Clin Infect. Dis. 16:677-688.
22. Persons, D. A., M. Laughlin, D. Tanner, J. Perfect, J. P. Gockerman, and J. W. Hathorn. 1991. Fluconazole and Candida krusei fungemia. N. Engl. J. Med. 325:1315.
23. Pfaller, M., and R. Wenzel. 1992. Impact of the changing epidemiology of fungal infections in the 1990s. Eur. J. Clin. Microbiol. Infect. Dis. 11:287-291.
24. Pfaller, M. A. 1994. Epidemiology and control of fungal infections. Clin Infect. Dis. 19(Suppl. 1):S8-S13.
25. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22(Suppl. 2):S89-S94.
26. Pittet, D., L. Ning, R. F. Woolson, and R. P. Wenzel. 1997. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin. Infect. Dis. 24:1068-1078.
27. Powderly, W. G. Resistant candidiasis. 1994. AIDS Res. Hum. Retreviruses 10:925-929.
28. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, and C. D. Webb. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
29. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
30. Sangeorzan, J. A., S. F. Bradley, X. He, L. T. Zarins, G. L. Ridenour, R. N. Tiballi, and C. A. Kauffman. 1994. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med. 97:339-346.
31. Sanguineti, A., J. K. Carmichael, and K. Campbell. 1993. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch. Intern. Med. 153:1122-1124.
32. Tumbarello, M., G. Caldarola, E. Tacconelli, G. Morace, B. Posteraro, R. Cauda, and L. Ortona. 1996. Analysis of risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. J. Antimicrob. Chemother. 38:691-699.
33. Vazquez, J. A., V. Sanchez, C. Dmuchowski, L. M. Dembry, J. D. Sobel, and M. J. Zervos. 1993. Nosocomial acquisition of Candida albicans: an epidemiologic study. J. Infect. Dis. 168:195-201.
34. Wade, J. C. 1993. Epidemiology of Candida infections, p. 85-107. In G. P. Bodey (ed.), Candidiasis: pathogenesis, diagnosis and treatment. Raven Press, Ltd., New York, N.Y.
35. Wenzel, R. P. 1995. Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. 20:1531-1534.
36. White, A., and M. B. Goetz. 1994. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin. Infect. Dis. 19:687-692.
37. Wingard, J. R. 1994. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. 19(Suppl 1): S49-S53.
38. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.
39. Winston, D. J., P. H. Chandrasekar, H. M. Lazarus, J. L. Goodman, J. L. Silber, H. Horowitz, R. K. Shadduck, C. S. Rosenfeld, W. G. Ho, M. Z. Islam, et al. 1993. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann. Intern. Med. 118:495-503.